DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says reinforces the need to broaden CGM access beyond insulin-treated ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Highly anticipated presentation of results from the ...

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...

Hello Health Rounds readers. Today we highlight a study that found benefits of wearable glucose monitoring devices for all ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...

Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C ...

DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of ...